澳大利亚国家健康与医学研究委员会(NHMRC)于周一发布临时建议,指出在多方共同决策且评估合适的情况下,可考虑对已发育的年轻跨性别者使用青春期阻滞剂 1。该建议在公开征求意见期间将持续至1月18日,而完整的临床指南预计将在2028年左右制定完成 1。联邦卫生部长Mark Butler强调数据表明此类治疗实际应用极少,墨尔本最大的本地性别诊所在八年内平均仅向8名年轻人开具了处方,平均等待时间长达530天 1。
尽管联邦执政党及反对派绿党、自由党均倾向于遵循基于证据的医学指导,但部分州和领地政府选择了拒绝采纳 1。昆士兰州和北领地的公共卫生医院目前继续禁止向18岁以下儿童处方青春期阻滞剂,其中昆士兰州早在2025年1月便依据英国Hilary Cass审查中关于“早期抑制证据基础非常薄弱”的结论引入了禁令 1。政治反应呈现两极化:绿党领袖David Shoebridge支持遵循专家建议并批评政治家将此作为政治工具,自由党参议员Andrew Bragg虽警告不要将跨性别群体当作“政治足球”,但也承认仅在极少数情况下治疗可能是适当的 1。与此同时,One Nation政党发言人明确表示,若其能在维多利亚州或联邦赢得选举,将致力于在全国范围内禁止此类治疗 1。
The Australian National Health and Medical Research Council (NHMRC) released interim recommendations on Monday supporting the use of puberty blockers for young transgender individuals under specific conditions. 1 The guidance states that such treatment may be considered for those who have undergone puberty and are deemed appropriate through a shared decision-making process. 1 While the federal government, opposition parties, and the Greens welcomed this evidence-based advice, Queensland and the Northern Territory explicitly rejected it, maintaining their bans on prescribing these medications to children under 18 in public hospitals. 1
Health Minister Mark Butler cited data from Melbourne’s largest local gender clinic, noting that over an eight-year period, an average of only eight young people received prescriptions for puberty blockers, with an average waiting time of 530 days. 1 Green Party leader David Shoebridge endorsed following medical expert advice, criticizing politicians for using the issue as a political tool. 1 Liberal Senator Andrew Bragg warned against treating the transgender community as "political football," while acknowledging that such treatment might be suitable in rare cases. 1 Conversely, One Nation stated that if they win elections in Victoria or at the federal level, they will seek to ban such treatments nationwide. 1
Queensland introduced its ban in January 2025, citing the UK’s Hilary Cass review which concluded that the evidence base for early suppression is "very weak." 1 The NHMRC’s interim recommendation remains open for public comment until January 18, with final clinical guidelines expected to be developed around 2028. 1
评论
还没有评论,欢迎留下第一条。